Precision Biosciences (DTIL) Income towards Parent Company (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Income towards Parent Company data on file, last reported at -$8.4 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$8.4 million, up 60.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$36.6 million (up 6.76% YoY), and the FY2025 annual result was $885000.0, changed N/A from the prior year.
• Income towards Parent Company fell to -$8.4 million in Q1 2026 per DTIL's latest filing, from $12.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $25.4 million in Q2 2024 and troughed at -$29.5 million in Q2 2022.
• A 5-year average of -$10.1 million and a median of -$9.1 million in 2022 frame the typical range for Income towards Parent Company.
• On a YoY basis, Income towards Parent Company climbed as much as 387.07% in 2024 and fell as far as 731.66% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$9.1 million in 2022, then soared by 68.49% to -$2.9 million in 2023, then plunged by 731.66% to -$23.7 million in 2024, then soared by 154.47% to $12.9 million in 2025, then plunged by 164.85% to -$8.4 million in 2026.
• Business Quant data shows DTIL's Income towards Parent Company at -$8.4 million in Q1 2026, $12.9 million in Q4 2025, and -$20.0 million in Q3 2025.